Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 20/20 | 0.58 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.56 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26626064 | 1.00 | LGALS3 (0.58) | LGALS3LGALS9LGALS1 | |
| SCHEMBL29646614 | 1.00 | LGALS3 (0.58) | LGALS3LGALS9LGALS1 | |
| SCHEMBL26626075 | 0.96 | LGALS3 (0.59) | LGALS3LGALS9LGALS1 | |
| SCHEMBL26625993 | 0.96 | LGALS3 (0.59) | LGALS3LGALS9LGALS1 | |
| SCHEMBL29646625 | 0.96 | LGALS3 (0.59) | LGALS3LGALS9LGALS1 | |
| SCHEMBL29646566 | 0.96 | LGALS3 (0.59) | LGALS3LGALS9LGALS1 | |
| SCHEMBL29646567 | 0.96 | LGALS3 (0.59) | LGALS3LGALS9LGALS1 | |
| SCHEMBL29646573 | 0.96 | LGALS3 (0.60) | LGALS3LGALS9LGALS1 | |
| SCHEMBL26626061 | 0.96 | LGALS3 (0.60) | LGALS3LGALS9LGALS1 | |
| SCHEMBL26626074 | 0.96 | LGALS3 (0.60) | LGALS3LGALS9LGALS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12291520-B2 | Galectin-3 inhibiting 2-hydroxycycloalkane-1-carbamoyl derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-05-06 | — | — | US | claimed |
| EP-4237419-A1 | GALECTIN-3 INHIBITING 2-HYDROXYCYCLOALKANE-1 -CARBAMOYL DERIVATIVES | Idorsia Pharmaceuticals Ltd (CH) | 2023-09-06 | — | — | EP | claimed |
| WO-2022090544-A1 | GALECTIN-3 INHIBITING 2-HYDROXYCYCLOALKANE-1 -CARBAMOYL DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-05-05 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12291520-B2 | Galectin-3 inhibiting 2-hydroxycycloalkane-1-carbamoyl derivatives | LGALS1, LGALS2, LGALS3 | LGALS3 3/4885LGALS9 6/4885LGALS1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.